Erratum to: Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: An observational study from Southern India (United European Gastroenterology Journal, (2014), 2, 5, (397-405), 10.1177/2050640614546947);Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: An observational study from southern India

United European Gastroenterology Journal

Volumn 2, Issue 5, 2014, Pages 397-405

  Larsson, Geir ^a,b   Shenoy, Koticherry Thrivikrama ^c   Ramasubramanian, Ramalingom ^d   Thayumanavan, Lakshmikanthan ^e   Balakumaran, Leena Kondarappassery ^c   Bjune, Gunnar A ^b   Moum, Bjørn A ^f  

^a LOVISENBERG DIAKONALE HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c GOVERNMENT MEDICAL COLLEGE   (India)

^d Thoothukudi Government Medical College   (India)

^e Government Rajaji Hospital   (India)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Biomarker; Calprotectin; Clinical features; CRP; Diagnosis; Follow up; Intestinal tuberculosis; Pulmonary tuberculosis; Treatment response

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN;

ABDOMINAL MASS; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CACHEXIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COUGHING; FATIGUE; FECES ANALYSIS; FEMALE; FEVER; FOLLOW UP; HUMAN; INTESTINE TUBERCULOSIS; LUNG TUBERCULOSIS; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; VERNER MORRISON SYNDROME; WEIGHT REDUCTION;

EID: 85006201226     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640614561156     Document Type: Erratum

References (35)

1. Muruganathan A, Thomas A, Muniyandi M, et al. Revised National Tuberculosis Control Programme (RNTCP). J Indian Med Assoc 2010; 108: 868–870.
2. Li X, Liu X, Zou Y, et al. Predictors of clinical and endoscopic findings in differentiating Crohn’s disease from intestinal tuberculosis. Dig Dis Sci 2011; 56: 188–196.
3. Epstein D, Watermeyer G and Kirsch R. Review article: The diagnosis and management of Crohn’s disease in populations with high-risk rates for tuberculosis. Aliment Pharmacol Ther 2007; 25: 1373–1388.
4. Makharia GK, Srivastava S, Das P, et al. Clinical, endoscopic, and histological differentiations between Crohn’s disease and intestinal tuberculosis. Am J Gastroenterol 2010; 105: 642–651.
5. Alvares JF, Devarbhavi H, Makhija P, et al. Clinical, colonoscopic, and histological profile of colonic tuberculosis in a tertiary hospital. Endoscopy 2005; 37: 351–356.
6. Patel N, Amarapurkar D, Agal S, et al. Gastrointestinal luminal tuberculosis: establishing the diagnosis. J Gastroenterol Hepatol 2004; 19: 1240–1246.
7. Li Y, Zhang LF, Liu XQ, et al. The role of in vitro interferongamma-release assay in differentiating intestinal tuberculosis from Crohn’s disease in China. J Crohns Colitis 2012; 6: 317–323.
8. Tai WP, Hu PJ, Zhai HZ, et al. The clinical analysis of 34 cases of intestinal tuberculosis in China’s big city hospitals. Int J Colorectal Dis 2011; 26: 1339–1343.
9. Larsson G, Shenoy K, Ramasumubramian R, et al. Routine diagnosis of intestinal tuberculosis and Crohn’s Disease in Southern India. World J Gastroenterol 2014; 20: 5017–5024.
10. Thomas TA, Mondal D, Noor Z, et al. Malnutrition and helminth infection affect performance of an interferon gamma-release assay. Pediatrics 2010; 126: 1522–1529.
11. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997; 50: 113–123.
12. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 2000; 47: 506–513.
13. Striz I and Trebichavsky I. Calprotectin-a pleiotropic molecule in acute and chronic inflammation. Physiol Res 2004; 53: 245–253.
14. Gopal R, Monin L, Torres D, et al. S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis. Am J Respir Crit Care Med 2013; 188: 1137–1146.
15. Lobaton T, Lopez-Garcia A, Rodriguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J Crohns Colitis 2013; 7: e641–e651.
16. D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2218–2224.
17. Logan VS. Anorectal tuberculosis. Proc R Soc Med 1969; 62: 1227–1230.
18. Pugazhendhi S, Jayakanthan K, Pulimood AB, et al. Cytokine gene expression in intestinal tuberculosis and Crohn’s disease. Int J Tuberc Lung Dis 2013; 17: 662–668.
19. Gisbert JP, Bermejo F, Perez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009; 15: 1190–1198.
20. Sipponen T, Savilahti E, Kolho KL, et al. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 2008; 14: 40–46.
21. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162–169.
22. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63–70.
23. Pavlidis P, Chedgy FJ and Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. Scand J Gastroenterol 2013; 48: 1048–1054.
24. Rasheed S, Zinicola R, Watson D, et al. Intra-abdominal and gastrointestinal tuberculosis. Colorectal Dis 2007; 9: 773–783.
25. Pettengell KE, Larsen C, Garb M, et al. Gastrointestinal tuberculosis in patients with pulmonary tuberculosis. Q J Med 1990; 74: 303–308.
26. Chang B, Wu AW, Hansel NN, et al. Quality of life in tuberculosis: A review of the English language literature. Qual Life Res 2004; 13: 1633–1642.
27. Rajeswari R, Muniyandi M, Balasubramanian R, et al. Perceptions of tuberculosis patients about their physical, mental and social well-being: A field report from south India. Soc Sci Med 2005; 60: 1845–1853.
28. Van CR, Karyadi E, Netea MG, et al. Decreased plasma leptin concentrations in tuberculosis patients are associated with wasting and inflammation. J Clin Endocrinol Metab 2002; 87: 758–763.
29. Tandon RK, Bansal R, Kapur BM, et al. A study of malabsorption in intestinal tuberculosis: Stagnant loop syndrome. Am J Clin Nutr 1980; 33: 244–250.
30. Sahin F and Yildiz P. Distinctive biochemical changes in pulmonary tuberculosis and pneumonia. Arch Med Sci 2013; 9: 656–661.
31. Sevgi DY, Derin O, Alpay AS, et al. Extrapulmonary tuberculosis: 7 year-experience of a tertiary center in Istanbul. Eur J Intern Med 2013; 24: 864–867.
32. Herlina M, Nataprawira HM and Garna H. Association of serum C-reactive protein and leptin levels with wasting in childhood tuberculosis. Singapore Med J 2011; 52: 446–450.
33. Amarapurkar DN, Patel ND and Rane PS. Diagnosis of Crohn’s disease in India where tuberculosis is widely prevalent. World J Gastroenterol 2008; 14: 741–746.
34. Yu H, Liu Y, Wang Y, et al. Clinical, endoscopic and histological differentiations between Crohn’s disease and intestinal tuberculosis. Digestion 2012; 85: 202–209.
35. Mukewar S, Mukewar S, Ravi R, et al. Colon tuberculosis: Endoscopic features and prospective endoscopic follow-up after anti-tuberculosis treatment. Clin Transl Gastroenterol 2012; 3